1. Overview
  2. All Stocks
  3. QIAGEN N.V

QIAGEN (QGEN.US) Price Target and Rating 2026/2027

43.97
Analysis framework by , founder of TradeDesk · Data: EODHD, official filings (SEC) · Updated
Share this analysis:

QIAGEN Price Target 2026: Analysts See 5% Upside

The average price target for QIAGEN is $46.07. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 4.79% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is QIAGEN overvalued or undervalued?

QIAGEN is currently fairly valued with a gap of 4.8% relative to the price target.


The current price is $43.97, which places QIAGEN in the fairly valued category. The stock is considered undervalued when the price is below $41.46, and overvalued when the price exceeds $50.68.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For QIAGEN, the fair value range lies between $41.46 and $50.68.


See the full price target analysis for QIAGEN →

↑ Back to navigation

Analyst Ratings for QIAGEN stock in 2026: Buy

16 analysts cover QIAGEN. The ratings are mixed, with 56.3% Buy, 43.8% Hold and 0% Sell. The average price target is $46.07, which gives an upside of 4.8% from the current price.

Consensus: Buy (3.94/5)
Strong Buy
6 (37.5%)
Buy
3 (18.8%)
Hold
7 (43.8%)
Strong Sell Sell Hold Buy Strong Buy
3.94 out of 5 based on 16 analysts
↑ Back to navigation

About QIAGEN – Diagnostics & Research

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands. Read more about the company

Key Figures for QIAGEN

$ 9.3B Market cap
$ 2.1B Revenue
Diagnostics & Research Industry
22.68 P/E
4.41 P/S
2.74 P/B
USA Listed on exchange
qiagen.com Website
Healthcare Sector

What kind of stock is QIAGEN?

Quality stock

QIAGEN is classified as a quality stock with a Piotroski score of 7/9 and a quality score in the top 22% of all stocks.

Score Overview for QIAGEN

💰 Value Score 55/100 (Neutral)
⭐ Quality Score 78/100 (High)
🚀 Momentum Score 64/100 (High)
📊 Total Score 65/100

📈 Valuation

QIAGEN trades at a P/E ratio of 22.7, which is close to the market average. The forward P/E is 14.0 (38% lower), which suggests the market expects rising earnings. The P/S ratio is 4.4. The P/B ratio is 2.7. The PEG ratio is 1.12.

💵 Profitability & Growth

QIAGEN has a profit margin of 19.5% (solid) and an operating margin of 26.3%. Return on equity (ROE) is 11.9% — solid return on equity. Return on assets (ROA) is 5.9%. The latest quarterly earnings grew 13.6% year over year.

🏦 Financial Health

The Piotroski score is 7 out of 9 — good financial health. Altman Z2 is 4.72 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 59.5% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 4.51%.

↑ Back to navigation

QIAGEN Dividend 2026: 0.8% Dividend Yield

Dividend Key Figures for QIAGEN in 2026

Dividend yield
0.82%
Payout ratio
1.9%
Low

When does QIAGEN pay a dividend in 2026?

Next dividend payment
July 14, 2026

How much does QIAGEN pay in dividends?

QIAGEN does not currently pay a dividend. This may be because the company reinvests its profits in growth, or because there is not enough profit for dividend payments. You can find more information about the dividend policy on the company's website.

Historical Dividend Payments for QIAGEN

No historical dividend payments are registered for this stock.

Ex-datePayment dateAmountCurrencyPeriod
No historical dividend payments available.
↑ Back to navigation

QIAGEN Short Selling 2026: 4.5% Sold Short

Moderate short interest: 4.5% of the free float
Short % of free float
4.5%
Assessment
Moderate short interest
Short squeeze risk
Low
Data source
SEC
Updated daily
The stock has a moderate share of short selling. Between 2-5% of the freely traded shares are sold short, which is within the normal range for most stocks.

Data is updated daily based on official filings with the SEC.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
4.5%

↑ Back to navigation

When Does QIAGEN Report Earnings?

The next earnings date for QIAGEN is not yet available. Check the company's investor calendar for more information.



↑ Back to navigation

Technical Analysis of QIAGEN 2026 – Signal: Strong Buy

Overall Technical Signal: Strong Buy

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 22, 2026.

Trend Analysis of QIAGEN N.V

QIAGEN N.V is in a short-term uptrend. The price of $44.90 is 5.6% above the 20-day average ($42.50). Medium term, the picture is positive: the price is 12.8% above the 50-day average ($39.79). Long term, the stock is 11.7% above the 200-day average ($40.18), which confirms a long-term uptrend.

Death Cross: The 50-day average (39.79) is below the 200-day average (40.18), which is a classic bearish signal for QIAGEN N.V.

Is QIAGEN N.V overbought or oversold?

QIAGEN N.V has an RSI of 68.4. The stock shows positive momentum in the upper part of the neutral zone. Combined with the positive trend, this supports the bullish picture.

MACD Analysis for QIAGEN N.V

Daily MACD: MACD is positive (1.101), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is above the signal line (1.071) by 0.030, which confirms rising momentum in the uptrend.

Weekly MACD: MACD5 is positive (0.622), which indicates a broader bullish long-term trend. MACD5 is above the signal line (-0.615) by 1.237, which confirms rising long-term momentum.

Overall MACD assessment: Both the daily and weekly MACD are positive and above their signal lines. Trend and momentum confirm each other across time horizons – the strongest bullish signal.

Risk Profile for QIAGEN N.V

QIAGEN N.V has an annual standard deviation of 35.0%, which classifies the stock as medium risk. The price can swing noticeably when the market moves.

Overall Technical Conclusion for QIAGEN N.V

Trend: Positive. The price trades above SMA50 and SMA200.

MACD trend (zero line): Daily bullish (1.101). Weekly bullish (0.622).

MACD momentum (signal): Daily rising. Weekly rising.

RSI: 68.4 – neutral.

Technical signal: Strong Buy

The price is in an uptrend (above SMA50/SMA200) and MACD is positive on both a daily and weekly basis. Trend and MACD trend confirm each other – the strongest technical buy signal.

↑ Back to navigation

Frequently Asked Questions About QIAGEN stock in 2026

Should you buy QIAGEN stock now?
Yes, the technical signal for QIAGEN is currently BUY. QIAGEN trades at $43.97 as of 8/22/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 1.101 with rising momentum (signal: 1.071); RSI is at 68.4 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $46.07 points to 4.8% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for QIAGEN stock?
The average analyst price target for QIAGEN is $46.07. The current price is $43.97, which gives an upside of 4.8%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $41.46 and $50.68.
Is QIAGEN a dividend stock?
Yes, QIAGEN is a dividend stock with a dividend yield of 0.82%. The payout ratio is 1.9%, which is considered sustainable. The next dividend payment is scheduled for 7/14/2026.
When does QIAGEN pay a dividend in 2026?
QIAGEN pays its next dividend on 7/14/2026. The dividend yield is 0.82%. The payout ratio of 1.9% points to a sustainable dividend with room to grow.
What is the risk of QIAGEN stock?
QIAGEN is rated as a stock in the risk category Moderate. the annual standard deviation is 35.0%, which classifies the stock as Moderate.
Is QIAGEN overvalued?
QIAGEN is considered fairly valued – the price is close to the analyst price target. QIAGEN has the following valuation ratios: a P/E ratio of 22.7 (moderately to highly valued), a P/S ratio of 4.4, a P/B ratio of 2.7. The stock trades close to the analyst price target and is considered fairly valued.
Is QIAGEN overbought?
No, QIAGEN is not overbought. RSI is at 68.4 (neutral zone). The technical indicators show: RSI is at 68.4 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 3.4% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next QIAGEN earnings report?
The date of the next earnings report for QIAGEN has not been published yet. Check the company's investor calendar for updates.
Is QIAGEN shorted?
Yes, QIAGEN is shorted with 4.5% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying QIAGEN stock?
There is currently no registered insider trading for QIAGEN.
Is QIAGEN a good stock?
Based on our total score, QIAGEN is rated as a good stock with a total score of 66 out of 100. The stock scores above average on value, quality and momentum – it is among the top 34% in our database. The score is made up of Value: 55/100, Quality: 78/100, Momentum: 64/100. In addition: a dividend of 0.82%; technical signal: Strong Buy. Whether QIAGEN is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for QIAGEN stock?
The outlook for QIAGEN based on current data: the average analyst price target is $46.07 (+4.8%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 22.7 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is QIAGEN stock rising?
QIAGEN is rising right now. The technical indicators show: the price is 3.4% above the 20-day average; MACD is positive with rising momentum (bullish signal). For the latest context, see our technical analysis, insider section and news overview above.
How high can QIAGEN go?
The average analyst price target for QIAGEN is $46.07, which corresponds to a potential gain of 4.8% from the current price of $43.97. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can QIAGEN fall?
We lack enough history to give a specific floor for QIAGEN. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does QIAGEN do?
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processin... The company belongs to the Healthcare sector, more specifically the Diagnostics & Research industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate QIAGEN as an investment.
Did QIAGEN raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from QIAGEN. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is QIAGEN making money or losing money?
Yes, QIAGEN is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 19.5% — which is solid. The operating margin (profit before interest and taxes) is 26.3%. At a P/E ratio of 22.7, you currently pay 22.7 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can QIAGEN go bankrupt?
The bankruptcy risk of QIAGEN is rated as low. Altman Z2 (a model for assessing financial distress) is 4.72 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 59% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does QIAGEN have a lot of debt?
No, QIAGEN has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 59%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can QIAGEN service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 14.1x, and net debt equals 1.2 years of earnings (EBITDA).
↑ Back to navigation

Explore More